Literature DB >> 28766198

Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database.

Lindsay K Hessler1, Jason K Molitoris2, Paula Y Rosenblatt3, Emily C Bellavance1, Elizabeth M Nichols2, Katherine H R Tkaczuk3, Steven J Feigenberg2, Soren M Bentzen4, Susan B Kesmodel5.   

Abstract

BACKGROUND: Occult breast cancer (OBC) is rare and optimal local-regional (LR) management has not been defined. Using a patient registry database, we examine factors associated with treatment and outcomes in OBC.
METHODS: Female patients with cT0 N1/2 M0 BC were selected from the National Cancer Database (2004-2013) and categorized into four treatment groups: MAST = mastectomy with axillary lymph node dissection (ALND) ± radiation (RT); RT + ALND = RT with ALND, no breast surgery; ALND = ALND alone; OBS = no breast surgery, RT, or ALND. Patient characteristics and overall survival (OS) were compared between groups, and multivariable analysis was used to identify factors associated with treatment and OS.
RESULTS: Among 2.03 million BC cases, 1853 females (0.09%) with cT0 N1/2 M0 disease were identified and 1231 patients were categorized into a treatment group: MAST = 592, RT + ALND = 342, ALND = 106, OBS = 191. On logistic regression, care at an academic center was associated with a higher likelihood of RT + ALND compared with MAST (odds ratio 2.03, 95% confidence interval [CI] 1.50-2.74, p < 0.001). Patients treated with RT + ALND had significantly better OS on univariate survival analysis compared with patients treated with MAST (hazard ratio [HR] 0.475, 95% CI 0.306-0.736, p = 0.001). RT + ALND was independently associated with OS on multivariable survival analysis (HR 0.509, 95% CI 0.321-0.808, p = 0.004), after adjusting for covariates.
CONCLUSIONS: Patients with OBC were more likely to undergo RT + ALND if they received care at an academic center. Patients treated with RT + ALND had significantly better OS compared with patients treated with MAST, after adjusting for covariates. This supports the use of RT + ALND as LR treatment for patients with OBC.

Entities:  

Mesh:

Year:  2017        PMID: 28766198     DOI: 10.1245/s10434-017-5928-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  4 in total

1.  Treatment for occult breast cancer: A propensity score analysis of the National Cancer Database.

Authors:  Catherine Tsai; Beiqun Zhao; Theresa Chan; Sarah L Blair
Journal:  Am J Surg       Date:  2019-11-11       Impact factor: 2.565

Review 2.  Occult breast cancer: Where are we at?

Authors:  Adam Ofri; Katrina Moore
Journal:  Breast       Date:  2020-10-27       Impact factor: 4.380

3.  Axillary metastasis from occult breast cancer and synchronous contralateral breast cancer initially suspected to be cancer with contralateral axillary metastasis: a case report.

Authors:  Myung Won Song; So Yeon Ki; Hyo Soon Lim; Hyo-Jae Lee; Ji Shin Lee; Jung Han Yoon
Journal:  BMC Womens Health       Date:  2021-12-17       Impact factor: 2.809

4.  Clinicopathological characteristics and treatment outcomes of occult breast cancer: a SEER population-based study.

Authors:  Li-Ping Ge; Xi-Yu Liu; Yi Xiao; Zong-Chao Gou; Shen Zhao; Yi-Zhou Jiang; Gen-Hong Di
Journal:  Cancer Manag Res       Date:  2018-10-09       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.